Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting

Abstract Introduction Real‐world data are critical to demonstrate the consistency of evidence and external generalizability of randomized controlled trials (RCTs). This study examined characteristics and outcomes of metastatic triple‐negative breast cancer (mTNBC) patients treated with eribulin mesy...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Sarah S. Mougalian, Ronda Copher, Jonathan K. Kish, Lindsay McAllister, Zhixiao Wang, Mary Broscious, David Garofalo, Janna Radtchenko, Bruce A. Feinberg
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2018-09-01
Serie:	Cancer Medicine
Soggetti:	eribulin metastatic breast cancer real‐world survival triple negative
Accesso online:	https://doi.org/10.1002/cam4.1705
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!